Visit us at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (past event)

We are now closer to our patients and healthcare professionals in the Middle East and Africa

Visit our MEA Website

Polish patients have a new website to rely on for ophthalmology and rheumatology

Visit the website

TRB Will be present at the European College of Sports and Exercise Physicians Congress (past event)

Visit us during the 7^th ECOSEP European College of Sports and Exercise Physicians Congress in Athens. We are looking forward to welcoming you at our stand n°9 from November 19 to 20, 2021.

Learn more

Watch the video of the conference “L’homme cérébral” that took place on March 13, 2021 (past event)

Magnoglia, TRB’s subsidiary in Monaco, was the main sponsor of the fully digital neuroscience conference “L’homme cérébral” that took place on March 13, 2021. This event was organised by the Fondation pour l’Étude du Système Nerveux (FESN) and focused on the theme “Memory”.

Watch the conference in English

Watch the conference in French

Our new Swiss website is now live, find out more about TRB products for Switzerland (past event)

We are thrilled to announce the launch of our new Swiss website available in four different languages (German, French, Italian and English).

We wanted to give our Swiss patients and health care professional the opportunity to know us better, who we are as a company and what we do for rheumatology and ophthalmology. By browsing through our website, you will be able to know more about our products available in Switzerland and our Swiss team.

We hope you enjoy this new website and feel free to let us know your thoughts on our social media.

Visit the website

Strong scientific presence of TRB at WCO IOF-ESCEO virtual congress 2020 (past event)

TRB is pleased to support the first 100% virtual WCO-IOF-ESCEO e-congress which will take place from August 20 to 22 and available online until November 20, 2020. We are waiting for your visit at our booth in the virtual exhibition area!

TRB is also proud to host a Satellite Symposium entitled “Hyaluronic acid efficacy in osteoarthritis: beyond standard clinical parameters” which will be available online until November 20, 2020. This Symposium, chaired by Prof. Jean-Yves Reginster, University of Liège, will focus on the use of additional endpoints in clinical trials evaluating the efficacy of intra-articular hyaluronic acid such as our Ostenil products in osteoarthritis.

In addition, two posters summarising post-hoc analyses of TRB-sponsored clinical trials will be presented during the congress. Dr. Maheu, APHP Hôpital St-Antoine, Paris, will present the results of a post-hoc analysis of OSTP-EUR-10-01, a study published last December in PLoS One. This analysis compares the various definitions of responders that can be used in osteoarthritis (PASS, OMERACT-OARSI, MCII) and aimed at identifying predictive factors of a better response following intra-articular injection of hyaluronic acid.

The second poster is focusing on diacerein, a symptomatic slow-acting drug for osteoarthritis (SYSADOA). Prof. Jean-Pierre Pelletier, University of Montréal Hospital Research Centre, will discuss a post-hoc analysis of the DISSCO trial (A multicentre study on the effect of DIacerein on Structure and Symptoms versus Celecoxib in Osteoarthritis) aimed at exploring the influence of patient age on the magnitude of response to treatment with diacerein. Data revealed no differences between the efficacy and safety profile of diacerein in knee osteoarthritis patients younger or older than 65 years of age.

We are looking forward to participating in the first virtual WCO-IOF-ESCEO congress and hope that you share our excitement!

Visit the virtual congress

COVID-19, how we adapt and respond to the situation.

The current COVID-19 pandemy impacts daily lives globally. As the crisis continues to evolve, it also shifts our ways of working and thinking. We at TRB are working hard to maintain our products and services and continue to make them available as we do during “normal times”.

As pharmaceutical company, it is at our core to safeguard and protect health. Our primary concern during this pandemy is therefore the protection of patients, doctors, pharmacists, associates and all our employees. The group prioritizes, wherever possible, home office until the situation is secure enough to allow everybody to work safely again, while some of our workforce still maintain a presence in our factories and offices.

TRB and its employees remain committed to keeping our services available for our patients, partners and customers, until the situation returns to normal. We like to thank everybody who is still working on-site or from home to help TRB deliver its services under the best possible conditions.

Thank you

Publication of a clinical trial evaluating Ostenil Plus in osteoarthritis

Geneva, January 15, 2020

TRB announces the publication of the results of a French multicenter, randomized, double-blind, controlled, non-inferiority study involving 292 patients with knee osteoarthritis, whose aim was to compare a single injection of Ostenil Plus (non-chemically modified 2% sodium hyaluronate) with a single injection of 0.8% hylan G‑F 20 (Synvisc‑One). “This study is the first face-to-face double-blind randomized controlled trial comparing the efficacy and safety of two single-shot hyaluronic acid preparations” said Dr. Emmanuel Maheu, first author of the publication, rheumatologist at Hôpital Saint-Antoine, AP-HP, Paris, France and in private practice.

Published in PLOS ONE, the results demonstrate that Ostenil Plus was non-inferior to hylan G‑F 20 in reducing pain measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scale six months after the injection, thus meeting the primary endpoint of the study. At this time point, Ostenil Plus led to a pain reduction of almost 60% versus baseline that was equivalent to hylan G‑F 20 treatment.

The analysis of secondary outcomes (including changes in joint stiffness, physical function, patient’s assessment of treatment efficacy, and rate of responders) did not show any statistically significant difference between Ostenil Plus and hylan G‑F 20 at any of the evaluated time points. From a safety point of view, both treatments were well tolerated. Adverse events were principally local and resolved spontaneously in most of the cases. Although the difference was not statistically significant, a higher proportion of hylan G‑F 20 patients (34.9%) than of Ostenil Plus patients (27.5%) reported treatment-emergent adverse events. In particular, injection site reactions and injection site joint pain were numerically higher in the hylan G‑F 20 group.

• One injection of Ostenil Plus (2% linear sodium hyaluronate) met the non-inferiority primary endpoint versus 0.8% hylan G‑F 20, which was the reduction in pain at 6 months post injection
• No difference was observed between Ostenil Plus and hylan G‑F 20 for any of the secondary endpoints
• Results of this multicenter, randomized, controlled trial were recently published in PLOS ONE journal

READ MORE

TRB Chemedica announces a collaboration with InnoMedica to develop liposomal GM1

TRB Chemedica International S.A. and InnoMedica Holding AG enter in a long-term relationship regarding the production of GM1 (monosialotetrahexosylganglioside) and its development as a liposomal formulation under the trade name Talineuren^®.

Geneva, January 7, 2019 – TRB Chemedica and InnoMedica signed recently a letter of intent, agreeing to collaborate for the production and development of GM1 as liposomal formulation. Gangliosides are sialic acid-containing glycosphingolipids that are naturally present in the plasma membrane of most vertebrate cells, particularly in the nervous system where they constitute up to 10% of the total lipid mass in the brain. They play important roles in many physiological processes including cell differentiation, apoptosis, neuronal protection and neutrotrophins release.¹ TRB Chemedica has dedicated significant research resources over many years to better understand the neuroprotective effects of GM1 on neurons and astrocytes to evaluate its potential in the treatment of neurological disorders.

InnoMedica started its venture in 2013. The independent pharmaceutical company develops innovative medicines in the field of liposomal drug delivery systems using a patent-protected technology platform. Liposomal GM1 is currently being developed as Talineuren^® for use in neurological diseases such as Parkinson’s disease, Huntington’s disease or amyotrophic lateral sclerosis. Thanks to its specific composition, Talineuren^® is able to cross the blood-brain barrier and to deliver drugs directly into the brain. This has been confirmed in preclinicial studies performed by InnoMedica in Parkinson’s and Huntington’s disease models. Liposomal formulation can be administrated orally, which is expected to simplify the mode of administration of GM1 as opposed to intravenously or intramuscularly injections and to reduce side effects.

TRB Chemedica’s GM1 is produced in Vouvry, Switzerland, under GMP conditions via a proprietary production process entirely developed and scaled up on the Vouvry site. A ganglioside powder is initially obtained after different steps of cleaning, extraction and purification. It constitutes the principal raw material of the GM1 active ingredient. This raw material undergoes various industrial and biochemical treatments, including concentration and dialyses. After this processing, it then goes through an ion exchange resin based column in order to obtain a high purity GM1.

The collaboration between TRB Chemedica and InnoMedica is considered strategically important for successful clinical translation and large-scale manufacturing of liposomal GM1. InnoMedica already uses TRB Chemedica’s GM1 for the production of Talineuren^® and TRB Chemedica agreed to adapt its production of GM1 based on Talineuren^® clinical development steps.

Learn more

References:

1. Aureli M, Mauri L, Ciampa MG, Prinetti A, Toffano G, Secchieri C, et al. GM1 ganglioside: Past studies and future potential. Mol Neurobiol. 2016;53(3):1824-42.